We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Genetic Markers Predict Susceptibility of Pancreatic Tumors

By LabMedica International staff writers
Posted on 18 Mar 2019
A panel of genetic markers allows clinicians to match pancreatic tumors with appropriate existing chemotherapeutic drugs.

Since it has been difficult to select suitable treatment for patients with pancreatic ductal adenocarcinomas (PDACs) based on genomic alterations, investigators at the University of Pittsburgh (PA, USA), performed targeted genomic profile analyses of a large number of PDACs to evaluate the full spectrum of treatable genomic alterations.

Previously, these investigators had developed "PancreaSeq", a clinical molecular test to evaluate common pancreatic cysts and identify which cases may progress to cancer. More...
The assay targets mutation detection by next generation sequencing in pancreatic cyst fluid fine needle aspiration (FNA) specimens. The PancreaSeq panel offers simultaneous sequencing and detection of mutations in eight pancreatic cancer-related genes (AKT1, CTNNB1, GNAS, KRAS, PIK3CA, PTEN, TP53, and VHL).

For the current study, the investigators performed targeted genomic profile analyses of 3594 PDAC samples from an international cohort, including capture-based targeted genomic profiling of as many as 315 cancer-associated genes and intron regions of 28 genes that were rearranged in cancer cells. Tumor mutation burden (TMB) and microsatellite instability (MSI) status were also assessed.

Results revealed that KRAS, TP53, CDKN2A, and SMAD4 were the most frequently altered genes in the PDAC tissues. KRAS mutations were found in 88% of samples. Among PDACs without mutations in KRAS, alterations were found in genes whose products were in the mitogen-activated protein kinase signaling pathway and were candidate drug targets, as well as gene fusions, gene amplifications, genes with missense mutations, and genes that contained deletions. Many of these encoded proteins in receptor tyrosine kinase, RAS, or mitogen-activated protein kinase signaling pathways. A genetic marker, which indicated that the tumor should be susceptible to existing chemotherapy drugs, was found in 17% percent of cases.

“Every pancreatic cancer is different, and performing molecular profiling of each patient’s tumor could help determine the best treatment options,” said first author Dr. Aatur Singhi, assistant professor of pathology at the University of Pittsburgh. “Rather than blindly giving patients the same chemotherapy, we want to tailor a patient’s chemo to their tumor type. A one-size-fits-all approach is not going to work. Therefore, we would like to make molecular profiling standard-of-care for patients with pancreatic cancer.”

The study was published in the March 2, 2019, online edition of the journal Gastroenterology.

Related Links:
University of Pittsburgh


New
Gold Member
Automatic CLIA Analyzer
Shine i9000
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.